ATYR PHARMA INC(ATYR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATYR ATYR PHARMA INC

Pre-Mkt 04-07 05:52:28 EDT

0.8240

-0.0229

-2.70%

High0.8664	Low0.8201	Vol728.78K
Open0.8400	D1 Closing0.8469	Amplitude5.47%
Mkt Cap80.74M	Tradable Cap79.08M	Total Shares97.99M
T/O609.46K	T/O Rate0.76%	Tradable Shares95.97M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ATYR","market":"US","secType":"STK","nameCN":"ATYR PHARMA INC","latestPrice":0.824,"timestamp":1775505600000,"preClose":0.8469,"halted":0,"volume":728780,"delay":0,"changeRate":-0.02703979218325662,"floatShares":95966000,"shares":97986634,"eps":-0.797093,"marketStatus":"Pre-Mkt","change":-0.0229,"latestTime":"04-07 05:52:28 EDT","open":0.84,"high":0.8664,"low":0.8201,"amount":609460.275866,"amplitude":0.05467,"askPrice":0.9647,"askSize":100,"bidPrice":0.8001,"bidSize":156,"shortable":3,"etf":0,"ttmEps":-0.797093,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1775568600000},"marketStatusCode":1,"adr":0,"listingDate":1430971200000,"exchange":"NASDAQ","adjPreClose":0.824,"postHourTrading":{"tag":"盘后","latestPrice":0.8404,"preClose":0.824,"latestTime":"18:02 EDT","volume":3074,"amount":2545.8336,"timestamp":1775512945495,"change":0.0164,"changeRate":0.019903,"amplitude":0.019903},"volumeRatio":0.5770782850827868,"impliedVol":2.4823,"impliedVolPercentile":0.8193},"requestUrl":"/m/hq/s/ATYR","defaultTab":"news","newsList":[{"id":"2625071366","title":"Analysts Offer Insights on Healthcare Companies: aTyr Pharma (ATYR) and Idexx Laboratories (IDXX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625071366","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625071366?lang=en_us&edition=fundamental","pubTime":"2026-04-07 06:30","pubTimestamp":1775514607,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on aTyr Pharma (ATYR) and Idexx Laboratories (IDXX). ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-atyr-pharma-atyr-and-idexx-laboratories-idxx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-atyr-pharma-atyr-and-idexx-laboratories-idxx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0690374615.EUR","IDXX","LU0690374961.EUR","LU1941712264.USD","LU1989771016.USD","XLV","BK4581","GB00B4LPDJ14.GBP","XBI","LABU","BK4082","GB00B4QBRK32.GBP","ATYR","LU0128526141.USD","LU2404859741.USD","HCSG","BK4588","BK4504","LU0170899867.USD","BK4137","BK4585","LU2404859667.USD","BK4139","LU0345774391.USD","LU1291159041.SGD","LU0345774631.USD","BK4567","LU1941712348.USD","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617528566","title":"Atyr Pharma Faces Nasdaq Delisting Risk After Minimum Bid Price Violation","url":"https://stock-news.laohu8.com/highlight/detail?id=2617528566","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617528566?lang=en_us&edition=fundamental","pubTime":"2026-03-07 14:00","pubTimestamp":1772863234,"startTime":"0","endTime":"0","summary":"Atyr Pharma Inc. (ATYR) has disclosed a new risk, in the Share Price & Shareholder Rights category. Atyr Pharma Inc. faces a significant listing ri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/atyr-pharma-faces-nasdaq-delisting-risk-after-minimum-bid-price-violation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/atyr-pharma-faces-nasdaq-delisting-risk-after-minimum-bid-price-violation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NQmain","BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617754655","title":"aTyr Pharma Q4 EPS $(0.14) Beats $(0.16) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2617754655","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617754655?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:03","pubTimestamp":1772744613,"startTime":"0","endTime":"0","summary":"aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 13.04 percent. This is a 22.22 percent increase over losses of $(0.18) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51082508/atyr-pharma-q4-eps-0-14-beats-0-16-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"aTyr Pharma Q4 EPS $(0.14) Beats $(0.16) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617751215","title":"aTyr posts FY 2025 net loss of USD 74.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617751215","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617751215?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:02","pubTimestamp":1772744535,"startTime":"0","endTime":"0","summary":"aTyr posts FY 2025 net loss of USD 74.1 million               aTyr Pharma reported a Q4 2025 net loss attributable to shareholders of USD 14.0 million, or USD 0.14 per share (basic and diluted), on no","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDLc9fMpk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","BK4139","BK4588","IE00B3QW5Z07.USD","SG9999014005.SGD","SG9999014013.SGD","SG9999014039.USD","BK4585","SG9999014021.USD","ATYR","LU2095319765.USD","BK4112","IE00B64PRP62.GBP","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617579237","title":"aTyr Pharma Inc: Qtrly Shr Loss $0.14","url":"https://stock-news.laohu8.com/highlight/detail?id=2617579237","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617579237?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:01","pubTimestamp":1772744461,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUA8PVVNF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617575947","title":"Press Release: aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2617575947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617575947?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:01","pubTimestamp":1772744460,"startTime":"0","endTime":"0","summary":"Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT study and determine the path forward for efzofitimod in pulmonary sarcoidosis.\"In 2025 we announced results from our Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease  where a significant proportion of patients develop chronic or progressive disease with debilitating symptoms despite current treatment options. This marked an important milestone, not only for the broader sarcoidosis community, but also for aTyr, as it was the Company's largest and first Phase 3 study of a tRNA synthetase-derived therapy generated from our platform,\" said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.\"We are ready and look forward to engaging with the U.S. Food and Drug Administration  in mid-April to review the results of the study and determine the path forward for efzofitimod in pulmonary sarcoidosis. We plan to pro","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","ATYR","BK4099","BK4604","03160","BK4555","TM","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613075292","title":"aTyr Pharma Awards Inducement Stock Options Under Nasdaq Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613075292","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613075292?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:01","pubTimestamp":1771621269,"startTime":"0","endTime":"0","summary":"aTyr Pharma said its board compensation committee granted two new employees nonstatutory stock options covering a total of 12,200 common shares at an exercise price of $0.98 per share. The options vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over the following three years, subject to continued employment. The awards were made under the company’s 2022 Inducement Plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via GlobeNewswire  on February 20, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL6Kw0J0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","SG9999014039.USD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4139","LU0314104364.USD","NDAQ","SG9999014005.SGD","BK4585","IE00B3QW5Z07.USD","SG9999014021.USD","ATYR","LU2095319765.USD","LU2210149790.SGD","BK4112","SG9999014013.SGD","IE00BGHQF748.EUR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613629205","title":"aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613629205","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613629205?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:01","pubTimestamp":1771621260,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nTUA6JTTJ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608487190","title":"BRIEF-Atyr Pharma Announces Scheduling Of FDA Type C Meeting To Discuss Efzofitimod Program In Pulmonary Sarcoidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2608487190","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608487190?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:25","pubTimestamp":1770125110,"startTime":"0","endTime":"0","summary":"BRIEF-Atyr Pharma Announces Scheduling Of FDA Type C Meeting To Discuss Efzofitimod Program In Pulmonary SarcoidosisFeb 3 (Reuters) - aTyr Pharma Inc ATYR.O:ATYR PHARMA ANNOUNCES SCHEDULING OF FDA TYP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nTUABTT2CV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2608838879","title":"aTyr Pharma Inc - Type C Meeting Scheduled for Mid-April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2608838879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608838879?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nTUABTT2CV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608687600","title":"aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2608687600","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608687600?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123604,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nTUABTT2CV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589643358","title":"aTyr Pharma Faces Class Action Lawsuit Over Securities Fraud Allegations","url":"https://stock-news.laohu8.com/highlight/detail?id=2589643358","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589643358?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:42","pubTimestamp":1765197737,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against aTyr Pharma Inc. on behalf of investors who suffered losses due to alleged securities fraud between November 7, 2024, and September 12, 2025. The lawsuit claims that the company made false and misleading statements and concealed material adverse information regarding the efficacy of its drug candidate, Efzofitimod, specifically its ability to allow patients to completely taper their steroid usage. The situation escalated when, on September 15, 2025, aTyr Pharma announced that its EFZO-FIT study did not meet its primary endpoint, leading to an 83.2% drop in the company's stock price in a single day. The law firm Levi & Korsinsky is representing shareholders in this case.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL9zM605:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"aTyr Pharma Faces Class Action Lawsuit Over Securities Fraud Allegations","news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589170838","title":"aTyr Pharma Faces Nasdaq Delisting Risk Over Sub-$1 Stock Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2589170838","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589170838?lang=en_us&edition=fundamental","pubTime":"2025-12-06 05:06","pubTimestamp":1764968802,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc. has received a deficiency notice from the Nasdaq Stock Market, indicating that its common stock has closed below the $1.00 minimum bid price requirement for 30 consecutive business days, as mandated by Nasdaq Listing Rule 5550. The company has 180 calendar days, until June 2, 2026, to regain compliance by maintaining a minimum closing bid price of at least $1.00 per share for 10 consecutive business days. If aTyr Pharma does not meet this requirement, it may be eligible for an additional 180-day compliance period, provided it satisfies other listing standards. Failure to regain compliance could result in the company's stock being delisted from the Nasdaq Capital Market. The company is actively monitoring the situation and evaluating options to address the deficiency.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL8VQzMM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589889291","title":"aTyr Pharma Reveals EFZO-FIT Study Failure in Investor Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2589889291","media":"Reuters","labels":["policyRegulatory","dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589889291?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:42","pubTimestamp":1764938539,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on December 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL5b24Sz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"aTyr Pharma Reveals EFZO-FIT Study Failure in Investor Call","news_tag":"policyRegulatory,dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588046898","title":"aTyr Pharma Faces Investor Class Action After Drug Trial Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046898","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588046898?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:39","pubTimestamp":1764765553,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc. is facing a class action securities lawsuit filed on behalf of investors who suffered losses between November 7, 2024, and September 12, 2025. The lawsuit alleges that aTyr Pharma made false and misleading statements and concealed material adverse information regarding the efficacy of its drug candidate, Efzofitimod, particularly its ability to enable patients to taper off steroid usage. The situation came to light on September 15, 2025, when the company announced that its EFZO-FIT study did not meet its primary endpoint. Following this announcement, the company's stock price dropped sharply from $6.03 to $1.02 per share, representing an 83.2% decline in a single day. The legal action seeks to recover losses for affected shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDLbdxwTt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588108058","title":"aTyr Pharma Reveals EFZO-FIT Study Missed Primary Endpoint in Investor Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2588108058","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588108058?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:39","pubTimestamp":1764679156,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on December 02, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL4LwsL5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586787834","title":"aTyr Pharma Faces Investor Lawsuit After Drug Trial Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2586787834","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586787834?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:42","pubTimestamp":1764074533,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against aTyr Pharma Inc. on behalf of investors who suffered losses due to alleged securities fraud between November 7, 2024 and September 12, 2025. The complaint alleges that the company made overly positive statements and concealed adverse information about the efficacy of its drug Efzofitimod, particularly regarding its ability to allow patients to fully taper steroid use. The litigation follows an investor call on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to the stock price plummeting from $6.03 to $1.02 per share in a single day. The case is being handled by Levi & Korsinsky, a law firm specializing in securities litigation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL6cHSxK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585148455","title":"aTyr Pharma Reveals Efzofitimod Trial Failure in Investor Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2585148455","media":"Reuters","labels":["policyRegulatory","dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585148455?lang=en_us&edition=fundamental","pubTime":"2025-11-21 20:42","pubTimestamp":1763728942,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 21, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL99J8b1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"aTyr Pharma Reveals Efzofitimod Trial Failure in Investor Call","news_tag":"policyRegulatory,dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584867949","title":"aTyr Pharma Faces Class Action After Stock Plummets on Failed Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2584867949","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584867949?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:44","pubTimestamp":1763556257,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against aTyr Pharma Inc. on behalf of investors who suffered losses due to alleged securities fraud between November 7, 2024 and September 12, 2025. The lawsuit claims that the company issued positive statements about the efficacy of its drug, Efzofitimod, while concealing material adverse facts about its ability to allow patients to completely taper steroid usage. The truth was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to a sharp decline in the company's stock price from $6.03 to $1.02 per share. The legal action seeks to recover damages for affected shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDLccFkFR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584556608","title":"aTyr Pharma Faces Investor Class Action Over Alleged Securities Fraud","url":"https://stock-news.laohu8.com/highlight/detail?id=2584556608","media":"Reuters","labels":["shareholding","policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584556608?lang=en_us&edition=fundamental","pubTime":"2025-11-18 07:30","pubTimestamp":1763422215,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against aTyr Pharma Inc. on behalf of investors who suffered losses due to alleged securities fraud between November 7, 2024, and September 12, 2025. The legal action claims that the company misled shareholders, resulting in financial losses. The case is being handled by the law firm Levi & Korsinsky, which has a history of representing investors in complex securities litigation and recovering significant sums for affected shareholders. Investors who experienced losses during the specified period are encouraged to seek more information about their potential eligibility in the lawsuit.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate thi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL99x9N7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"aTyr Pharma Faces Investor Class Action Over Alleged Securities Fraud","news_tag":"shareholding,policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.atyrpharma.com","stockEarnings":[{"period":"1week","weight":0.1274},{"period":"1month","weight":0},{"period":"3month","weight":0.1377},{"period":"6month","weight":-0.176},{"period":"1year","weight":-0.6855},{"period":"ytd","weight":0.0522}],"compareEarnings":[{"period":"1week","weight":0.0427},{"period":"1month","weight":-0.02},{"period":"3month","weight":-0.0475},{"period":"6month","weight":-0.0211},{"period":"1year","weight":0.3041},{"period":"ytd","weight":-0.0337}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.727273,"avgChangeRate":0.035951},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.011862},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.068704},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.024246},{"month":5,"riseRate":0.5,"avgChangeRate":-0.058101},{"month":6,"riseRate":0.545455,"avgChangeRate":-0.018872},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.001577},{"month":8,"riseRate":0.181818,"avgChangeRate":-0.059775},{"month":9,"riseRate":0.454545,"avgChangeRate":0.014241},{"month":10,"riseRate":0.363636,"avgChangeRate":0.029504},{"month":11,"riseRate":0.545455,"avgChangeRate":0.024303},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.061175}],"exchange":"NASDAQ","name":"ATYR PHARMA INC","nameEN":"ATYR PHARMA INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ATYR PHARMA INC(ATYR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ATYR PHARMA INC(ATYR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ATYR PHARMA INC,ATYR,ATYR PHARMA INC股票,ATYR PHARMA INC股票老虎,ATYR PHARMA INC股票老虎国际,ATYR PHARMA INC行情,ATYR PHARMA INC股票行情,ATYR PHARMA INC股价,ATYR PHARMA INC股市,ATYR PHARMA INC股票价格,ATYR PHARMA INC股票交易,ATYR PHARMA INC股票购买,ATYR PHARMA INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ATYR PHARMA INC(ATYR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ATYR PHARMA INC(ATYR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction